{"filing":{"accession_number":"0001193125-26-340664","cik":"0001469443","ticker":"RKDA","company_name":"Arcadia Biosciences, Inc.","form":"8-K","filing_date":"2026-08-07","report_date":"2026-08-04","primary_document":"rkda-20260804.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1469443/000119312526340664/rkda-20260804.htm"},"events":[{"id":26263,"run_id":23855,"accession_number":"0001193125-26-340664","anchor_item_number":"3.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"summary":"Arcadia Biosciences received a formal notice from Nasdaq on August 4, 2026, that it has failed to satisfy the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). The company has been granted a 180-day compliance period until February 1, 2027, to regain compliance, with the explicit risk that failure to do so could result in delisting. This is a classic delisting-risk disclosure under Item 3.01.","company_name":"Arcadia Biosciences, Inc.","ticker":"RKDA","filing_date":"2026-08-07","form":"8-K","submitted_at":null,"items":[{"id":27313,"accession_number":"0001193125-26-340664","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"Arcadia Biosciences received a formal notice from Nasdaq on August 4, 2026, that it has failed to satisfy the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). The company has been granted a 180-day compliance period until February 1, 2027, to regain compliance, with the explicit risk that failure to do so could result in delisting. This is a classic delisting-risk disclosure under Item 3.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T10:03:41.435247+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27313,"accession_number":"0001193125-26-340664","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"Arcadia Biosciences received a formal notice from Nasdaq on August 4, 2026, that it has failed to satisfy the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). The company has been granted a 180-day compliance period until February 1, 2027, to regain compliance, with the explicit risk that failure to do so could result in delisting. This is a classic delisting-risk disclosure under Item 3.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T10:03:41.435247+00:00","company_name":"Arcadia Biosciences, Inc.","ticker":"RKDA","filing_date":"2026-08-07"}]}